News

Nerofe has received a new US patent for metastatic cancer treatmentNovember 21, 2018

21 Nov|

Phase2a Nerofe study has begun in Rabin and Kaplan medical centersSeptember 21, 2018

Phase2a Nerofe study has begun in Rabin and Kaplan medical centers

21 Sep|

PMWC 2018 conference – New Technology PresentedFebruary 4, 2018

At  PMWC 2018 conference Dr. Yoram Devary presented ISK new technology dealing with “personalized ImmunoOncology therapy” 

04 Feb|

New Article Published: Nerofe Phase I trial summaryDecember 11, 2017

The Phase I Nerofe (dTCApFs) human trial summary has been published in the Molecular and Clinical Oncology Journal.

In this trial Nerofe was found to be safe and well‑tolerated, and potentially efficacious as an anti-cancer agent.

11 Dec|

Successful completion of Phase I Nerofe Trial on Solid tumorsNovember 21, 2017

Successful completion of Phase I Nerofe Trial on Solid tumors

21 Nov|

Nerofe Pre-clinical Paper Published in Molecular and Clinical Oncology JournalOctober 21, 2017

Link To Article

21 Oct|

ISK is going to the BIO conference 2016March 29, 2016

ISK was selected for the 6th time to represent Israel in the BIO conference which is being held this year in San-Francisco.

29 Mar|

Nerofe’s Triple ActionNovember 1, 2015

Nerofe causes ER stress to different type of cells
NEROFE® TRIPLE-ACTION:
In Vitro assays have shown that Nerofe causes ER stress to cancer and endothelial cells, thus leading to cancer cell death and depletion of angiogenesis factors from serum, as seen in Phase Ia results. Because Immune cells express ST2 (Nerofe’s receptor), it is hypothesized

01 Nov|

Breakthrough – Cancer Immunotherapy Effects of NerofeSeptember 17, 2015

NerofeTM stimulates cancer cells attraction to APC and T cells and thereby inducing the death of cancer cells.

Recent FACS results have shown a significant increase in CD86 expressing cells in three types of malignant cells treated with NerofeTM.

CD86 is expressed by antigen-presenting cells, and it is the ligand for two proteins at the cell surface of T cells,

17 Sep|

ISK is going to the BIO conference 2015June 23, 2015

ISK was selected for the 5th time to represent Israel in the BIO conference in philadelphia

23 Jun|